Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
CAPR - Capricor Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$50.88
DETAILS
HIGH:
$62.00
LOW:
$38.00
MEDIAN:
$50.00
CONSENSUS:
$50.88
UPSIDE:
76.24%
Stock News
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics NASDAQ: CAPR said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku.
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints GMP manufacturing facility fully operational; second-floor expansion well underway Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected Cash balance of approximately $279 million expected to support operations into Q4 2027 Eligible for a Priority Review Voucher upon approval; PRV is transferable and monetizable, offering potential non-dilutive capital Conference call and webcast today at 4:30 p.m.
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing.
Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy
Capricor Therapeutics Inc. (NASDAQ:CAPR) on Thursday filed a lawsuit against Nippon Shinyaku Co., Ltd. and its U.S. subsidiary NS Pharma, Inc., alleging that flaws in the companies' U.S. distribution agreement for experimental Duchenne muscular dystrophy treatment Deramiocel could limit patient access to the therapy.
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026.
Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 25,000 Shares of Stock
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) CFO Anthony Bergmann sold 25,000 shares of the firm's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 61,265 Shares
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) Director Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The transaction was disclosed in a filing with the Securities and
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 53,735 Shares of Stock
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) Director Karimah Es Sabar sold 53,735 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $31.03, for a total value of $1,667,397.05. The transaction was disclosed in a document filed with the Securities and Exchange
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average – What’s Next?
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $26.80 and traded as high as $29.27. Capricor Therapeutics shares last traded at $27.77, with a volume of 745,376 shares traded. Wall Street Analyst
Contrasting Zimmer Biomet (NYSE:ZBH) and Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Zimmer Biomet (NYSE: ZBH - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Profitability This table compares Capricor Therapeutics and Zimmer
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel
Capricor Therapeutics is upgraded from 'Hold' to 'Buy' following FDA acceptance of the HOPE-3 clinical study report for Deramiocel in DMD cardiomyopathy. The FDA lifted the Complete Response Letter and set a PDUFA date of August 22, 2026, without requiring new studies, increasing regulatory clarity. Phase 3 HOPE-3 data showed Deramiocel slowed disease progression by 54% [PUL] and 91% [LVEF], with additional functional and fibrosis benefits.
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates
Capricor posted a quarterly loss of 62 cents per share, missing the consensus estimate of a 54-cent loss and worsening from a 16-cent loss in the prior-year period.
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update.
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced additional analyses and new functional outcomes data from the Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne muscular dystrophy (DMD), which were presented yesterday at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida.
Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review
Here's what investors need to know.
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has lifted the previously issued Complete Response Letter and resumed review of its Biologics License Application (“BLA”) seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy (“DMD”) cardiomyopathy. The submission has been classified as a Class 2 resubmission, with a Prescription Drug User Fee Act (“PDUFA”) target action date of August 22, 2026.
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has lifted the previously issued Complete Response Letter and resumed review of its Biologics License Application (“BLA”) seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy (“DMD”) cardiomyopathy. The submission has been classified as a Class 2 resubmission, with a Prescription Drug User Fee Act (“PDUFA”) target action date of August 22, 2026.
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center for Biologics Evaluation and Research (CBER), is set to leave his position in April.
Price Targets
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital
$38.00
(was $29.81)
Boobalan Pachaiyappan
·
Roth Capital
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald After Q4 Result
$62.00
(was $33.42)
Kristen Kluska
·
Cantor Fitzgerald
Capricor Therapeutics price target raised to $50 from $21 at B. Riley
$50.00
(was $26.12)
UBS
Capricor Therapeutics price target raised to $45 from $20 at Piper Sandler
$45.00
(was $27.38)
Piper Sandler
Capricor Therapeutics price target raised to $54 from $22 at Oppenheimer
$54.00
(was $26.89)
Oppenheimer
Capricor Therapeutics price target raised to $50 from $25 at Maxim
$50.00
(was $25.18)
Maxim Group
Capricor Therapeutics price target raised to $48 from $16 at Alliance Global
$48.00
(was $27.79)
Industrial Alliance Securities
Capricor Therapeutics price target raised to $60 from $24 at H.C. Wainwright
$60.00
(was $29.95)
H.C. Wainwright
Capricor Therapeutics price target raised to $13 from $12 at Roth Capital
$13.00
(was $6.20)
Boobalan Pachaiyappan
·
Roth Capital
Capricor Therapeutics price target lowered to $20 from $43 at Piper Sandler
$20.00
(was $7.66)
Edward Tenthoff
·
Piper Sandler
Capricor Therapeutics price target lowered to $24 from $77 at H.C. Wainwright
$24.00
(was $7.64)
Joseph Pantginis
·
H.C. Wainwright
Piper Sandler Starts Capricor Therapeutics (CAPR) at Overweight
$35.00
(was $9.43)
Edward Tenthoff
·
Piper Sandler
Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
$43.00
(was $8.89)
Leland Gershall
·
Oppenheimer
Capricor Therapeutics price target raised to $25 from $12 at Maxim
$25.00
(was $4.55)
Jason McCarthy
·
Maxim Group
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
$40.00
(was $2.78)
Joseph Pantginis
·
H.C. Wainwright
Capricor Therapeutics (CAPR) PT Raised to $15 at Oppenheimer
$15.00
(was $2.54)
Leland Gershall
·
Oppenheimer
Oppenheimer Starts Capricor Therapeutics (CAPR) at Outperform
$14.00
(was $2.82)
Leland Gershall
·
Oppenheimer